Katy Beckermann, MD, PhD – Vanderbilt University The phase 3 TiNivo-2 study (NCT04987203), sponsored by AVEO Pharmaceuticals, Inc., recently evaluated tivozanib (TIVO) combined with nivolumab (NIVO) versus TIVO monotherapy in patients with renal cell carcinoma (RCC) who progressed after immune checkpoint inhibitor (ICI) therapy. While the study didn’t meet its primary endpoint of improved … Continue reading Renal Cell Carcinoma TiNivo-2 Study: Patient-Reported Outcomes in Treatment Post-ICI